JP2021525248A5 - - Google Patents
Info
- Publication number
- JP2021525248A5 JP2021525248A5 JP2020565359A JP2020565359A JP2021525248A5 JP 2021525248 A5 JP2021525248 A5 JP 2021525248A5 JP 2020565359 A JP2020565359 A JP 2020565359A JP 2020565359 A JP2020565359 A JP 2020565359A JP 2021525248 A5 JP2021525248 A5 JP 2021525248A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- compound
- sequence number
- seq
- cdr1l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023093659A JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675639P | 2018-05-23 | 2018-05-23 | |
| US62/675,639 | 2018-05-23 | ||
| PCT/US2019/033505 WO2019226761A1 (en) | 2018-05-23 | 2019-05-22 | Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093659A Division JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525248A JP2021525248A (ja) | 2021-09-24 |
| JP2021525248A5 true JP2021525248A5 (enExample) | 2022-05-30 |
| JP7293256B2 JP7293256B2 (ja) | 2023-06-19 |
Family
ID=66999900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565359A Active JP7293256B2 (ja) | 2018-05-23 | 2019-05-22 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
| JP2023093659A Active JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093659A Active JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11439637B2 (enExample) |
| EP (2) | EP4218762A3 (enExample) |
| JP (2) | JP7293256B2 (enExample) |
| KR (1) | KR102813281B1 (enExample) |
| CN (2) | CN112399848B (enExample) |
| AU (1) | AU2019274530B2 (enExample) |
| BR (1) | BR112020023704A2 (enExample) |
| CA (1) | CA3101050A1 (enExample) |
| CY (1) | CY1126060T1 (enExample) |
| DK (1) | DK3796912T5 (enExample) |
| EA (1) | EA202092830A1 (enExample) |
| ES (1) | ES2945214T3 (enExample) |
| FI (1) | FI3796912T3 (enExample) |
| HR (1) | HRP20230449T1 (enExample) |
| HU (1) | HUE061792T2 (enExample) |
| IL (1) | IL278853B2 (enExample) |
| LT (1) | LT3796912T (enExample) |
| MX (1) | MX420366B (enExample) |
| PL (1) | PL3796912T3 (enExample) |
| PT (1) | PT3796912T (enExample) |
| RS (1) | RS64189B1 (enExample) |
| SG (1) | SG11202011545YA (enExample) |
| SI (1) | SI3796912T1 (enExample) |
| SM (1) | SMT202300142T1 (enExample) |
| WO (1) | WO2019226761A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4467143B1 (en) * | 2017-07-10 | 2026-03-11 | Celgene Corporation | Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile |
| KR102718800B1 (ko) | 2018-05-23 | 2024-10-18 | 셀진 코포레이션 | 다발성 골수종의 치료 및 4-(4-(4-(((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조니트릴에 대한 바이오마커의 용도 |
| CA3117978A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| JP2020103414A (ja) * | 2018-12-26 | 2020-07-09 | 株式会社三洋物産 | 遊技機 |
| SG11202107439XA (en) | 2019-01-09 | 2021-08-30 | Celgene Corp | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same |
| FI3908281T3 (fi) * | 2019-01-09 | 2024-10-01 | Celgene Corp | Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa |
| WO2020146441A1 (en) * | 2019-01-09 | 2020-07-16 | Celgene Corporation | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| LT3819007T (lt) | 2019-11-11 | 2024-10-10 | Amgen Research (Munich) Gmbh | Dozavimo režimas, skirtas anti-bcma agentams |
| KR20220124228A (ko) * | 2020-01-20 | 2022-09-13 | 강푸 바이오파마슈티칼즈 리미티드 | 이소인돌린 유도체, 및 이의 제약 조성물 및 용도 |
| JP2021133198A (ja) * | 2020-02-28 | 2021-09-13 | 株式会社三洋物産 | 遊技機 |
| JP2021133200A (ja) * | 2020-02-28 | 2021-09-13 | 株式会社三洋物産 | 遊技機 |
| JP2021133199A (ja) * | 2020-02-28 | 2021-09-13 | 株式会社三洋物産 | 遊技機 |
| US20230165872A1 (en) * | 2020-04-28 | 2023-06-01 | Juno Therapeutics, Inc. | Combination of bcma-directed t cell therapy and an immunomodulatory compound |
| CN115803027A (zh) | 2020-04-30 | 2023-03-14 | 百时美施贵宝公司 | 治疗细胞因子相关的不良事件的方法 |
| JP2021186294A (ja) * | 2020-05-29 | 2021-12-13 | 株式会社三洋物産 | 遊技機 |
| JP2022012090A (ja) * | 2020-06-30 | 2022-01-17 | 株式会社三洋物産 | 遊技機 |
| JP2022012088A (ja) * | 2020-06-30 | 2022-01-17 | 株式会社三洋物産 | 遊技機 |
| JP2022012089A (ja) * | 2020-06-30 | 2022-01-17 | 株式会社三洋物産 | 遊技機 |
| DK4178548T3 (da) | 2020-07-07 | 2024-08-19 | Celgene Corp | Farmaceutiske sammensætninger omfattende (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUORBENZONITRIL |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| EP4507790A1 (en) | 2022-04-11 | 2025-02-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN120857940A (zh) | 2023-02-17 | 2025-10-28 | 瑞泽恩制药公司 | 对cd3/taa双特异性抗体有反应的诱导型nk细胞 |
| WO2026059921A1 (en) * | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| SI3331910T1 (sl) | 2015-08-03 | 2020-07-31 | Engmab Sarl | Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA) |
| US10238225B2 (en) * | 2016-06-08 | 2019-03-26 | Windor Enterprises, LLC | Compression garment donning aid device, method, and kit |
| JP7100028B2 (ja) | 2016-10-20 | 2022-07-12 | セルジーン コーポレイション | セレブロン系のヘテロ二量体化可能なキメラ抗原受容体 |
| JP7267914B2 (ja) | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| EP4467143B1 (en) * | 2017-07-10 | 2026-03-11 | Celgene Corporation | Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile |
-
2019
- 2019-05-22 PL PL19732494.0T patent/PL3796912T3/pl unknown
- 2019-05-22 SI SI201930535T patent/SI3796912T1/sl unknown
- 2019-05-22 WO PCT/US2019/033505 patent/WO2019226761A1/en not_active Ceased
- 2019-05-22 US US16/419,971 patent/US11439637B2/en active Active
- 2019-05-22 SM SM20230142T patent/SMT202300142T1/it unknown
- 2019-05-22 LT LTEPPCT/US2019/033505T patent/LT3796912T/lt unknown
- 2019-05-22 BR BR112020023704-3A patent/BR112020023704A2/pt unknown
- 2019-05-22 MX MX2020012485A patent/MX420366B/es unknown
- 2019-05-22 AU AU2019274530A patent/AU2019274530B2/en active Active
- 2019-05-22 CN CN201980046500.XA patent/CN112399848B/zh active Active
- 2019-05-22 HU HUE19732494A patent/HUE061792T2/hu unknown
- 2019-05-22 CA CA3101050A patent/CA3101050A1/en active Pending
- 2019-05-22 HR HRP20230449TT patent/HRP20230449T1/hr unknown
- 2019-05-22 SG SG11202011545YA patent/SG11202011545YA/en unknown
- 2019-05-22 PT PT197324940T patent/PT3796912T/pt unknown
- 2019-05-22 EA EA202092830A patent/EA202092830A1/ru unknown
- 2019-05-22 IL IL278853A patent/IL278853B2/en unknown
- 2019-05-22 ES ES19732494T patent/ES2945214T3/es active Active
- 2019-05-22 KR KR1020207036733A patent/KR102813281B1/ko active Active
- 2019-05-22 RS RS20230351A patent/RS64189B1/sr unknown
- 2019-05-22 EP EP23156579.7A patent/EP4218762A3/en active Pending
- 2019-05-22 DK DK19732494.0T patent/DK3796912T5/da active
- 2019-05-22 CN CN202110586843.4A patent/CN113713095B/zh active Active
- 2019-05-22 JP JP2020565359A patent/JP7293256B2/ja active Active
- 2019-05-22 EP EP19732494.0A patent/EP3796912B1/en active Active
- 2019-05-22 FI FIEP19732494.0T patent/FI3796912T3/fi active
-
2022
- 2022-08-17 US US17/820,534 patent/US12053466B2/en active Active
-
2023
- 2023-05-15 CY CY20231100227T patent/CY1126060T1/el unknown
- 2023-06-07 JP JP2023093659A patent/JP7550922B2/ja active Active
-
2024
- 2024-06-25 US US18/753,467 patent/US20240366593A1/en active Pending